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The ability of one structural type to perform multiple medical diagnostic or therapeutic
functions is often cited as an advantageous characteristic of nanomaterials that cannot be
achieved with organic small molecules.[1–3] Although there are now many examples of
nanosystems that integrate multiple functions into a single structure, the designs can reduce
the efficacy of the individual functions due to space and surface-chemistry limitations in the
tiny platforms. For example, magnetic nanoparticles and drug molecules can be co-
encapsulated in liposomes to simultaneously perform multiple functions, such as magnetic
resonance imaging, magnetic drug delivery and hyperthermia,[4] but the loading capacity
and the stability are typically compromised relative to a single-component liposome. There
has been some effort to develop intrinsically multifunctional nanomaterials such as magnetic
nanocapsules and luminescent porous silicon nanoparticles to overcome such problems,[5,6]
although these more complicated structures may lose versatility in terms of the types of
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payloads they can carry. Access to the payloads can also be limited, reducing the ability to
control their release. Separating functions into two or more nanoparticle formulations is one
means to simplify the problem. If two separate nanomaterials can be engineered to
synergistically cooperate in their diagnostic or therapeutic functions, it is possible that the
overall dosage can be reduced, minimizing side effects and providing a safer transition to the
clinic.
Combination therapies are commonly employed in a wide range of cancer treatments. In
particular, hyperthermia can increase the concentration of an administered therapeutic
nanoparticle in a tumoral region by increasing blood flow and vessel permeability.[7,8]
Hyperthermia can also enhance drug toxicity in cancer cells that are otherwise resistant to
chemotherapeutics.[9] Furthermore, local hyperthermia can improve the accumulation of a
drug, which is encapsulated in a thermosensitive carrier.[10,11] The combination of
hyperthermia and chemotherapeutics can, therefore, be employed synergistically to treat
high-risk tumors with a goal of total tumor eradication. From a clinical perspective, precise
and site-specific heat transfer to a diseased site would improve the safety and efficacy of
thermal cancer therapies.
Recent advances in the field of plasmonic nanomaterials have presented new opportunities
for localized hyperthermia therapy. Plasmonic nanomaterials are metallic structures that
efficiently convert optical radiation into heat by coupling into one or more plasmon modes.
[12,13] Of particular interest are gold nanorods (GNRs) due to their large optical
coefficients in the NIR region of the spectrum, where living tissue is highly transparent.
[14,15] Previously, we and other groups demonstrated that GNRs can be modified to
circulate for long periods of time in the blood stream and passively accumulate in tumors in
vivo, where they can be heated with localized NIR radiation to selectively destroy malignant
tissue regions.[16–18] In addition, the optical properties of GNRs or gold-based
nanoparticles have been harnessed to image targeted tissues in vivo.[19–21] In this
Communication, we hypothesized that GNRs could be used to detect a diseased site and act
as tumor-specific triggers to amplify the therapeutic function of a circulating drug carrier
(Fig. 1a). We find that GNR-mediated photothermal heating is highly localized in tumors
and significantly improves the selectivity and efficacy of cancer treatment with
thermosensitive drug carriers.
Cetyltrimethylammonium bromide (CTAB)-coated GNRs were coated with a mixed
monolayer of poly(ethylene glycol) (PEG) and surface-enhanced Raman scattering (SERS)-
active reporter molecules to increase circulation times, reduce in vivo toxicity, and provide
remote imaging as described previously.[18,22] The gold cores appear as dark rods in the
transmission electron microscopy (TEM) image (Fig. 1b), with an average width of ~13 nm
and length of ~47 nm. The PEG coating is observed as a faint halo around the metal cores.
The wavelength of maximum optical absorption of the GNR is 800 nm (Supporting
Information, Fig. S1). As observed previously, intravenously injected PEG-coated GNRs
were observed to circulate in the blood stream with a half-life of >17 h in mice, enabling
passive accumulation in a xenografted MDA-MB-435 human melanoma tumor through the
porous vascular structures.[18] Passive accumulation in tumors allowed tunable
photothermal heating selectively in the tumor region by excitation with an 810 nm laser
(Fig. 1c and Fig. S2). As has been observed with SERS-tagged gold nanoparticles,[20,22]
the SERS spectrum of a surface-embedded cyanine dye on the GNRs was evident in Raman
spectra obtained from the tumor in vivo (Fig. 1c and Fig. S3). Thus, the GNR formulation
used in this study is an effective hyperthermia agent that can be observed in vivo with
spectroscopic imaging methods.
Park et al. Page 2
Adv Mater. Author manuscript; available in PMC 2011 March 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
A second nanostructure that could deliver a drug in response to the thermal stimulus from
the GNRs was synthesized using a modification of published preparations.[23,24] The
formulation contains thermally responsive lipid constituents chosen, in part, for their
potential for translation to clinical studies. Three preparations were studied: a thermally
sensitive liposome (TSL, 132.4 ±7.2 nm hydrodynamic size), a control liposome that is not
thermally sensitive (NSL, 137.1 ±4.9 nm hydrodynamic size), and a thermally sensitive
micelle (TSM, 25.9 ±2.1 nm hydrodynamic size). All three sample types were prepared with
the chemotherapeutic agent doxorubicin (DOX) in this study. The TSL displayed similar
thermal properties to the published formulation.[23,25] The TSLs released ~50–60% of their
drug contents in a short period of time (~30 s) when heated to 45 °C, while the nonthermally
sensitive liposomes showed no significant drug release (Fig. 1d and Fig. S4). The micellar
TSMs exhibited thermal sensitivity similar to that of the TSL, but they released their DOX
payload more slowly at 45 °C.
We next investigated if the thermally sensitive drug carriers could deliver DOX into cancer
cells at increased temperature in vitro (Fig. 2a). In the absence of drug, the cells were
observed to tolerate temperatures of ~45 °C without any significant indications of toxicity.
In the presence of the drug, free DOX molecules rapidly internalized into cells and bound to
nuclei either with or without heating, although more DOX was observed in the nuclei of the
cells heated to 45 °C. Of the three types of nanoparticles, TSLs delivered the largest quantity
of DOX to cells when heated, while TSMs exhibited much lower DOX delivery. As
expected, NSLs showed no temperature-induced DOX release, consistent with the lack of
thermally responsive lipids in their structure. None of the three nanoparticle types displayed
significant internalization of DOX into cells at 37 °C.
GNR-mediated photothermal heating significantly increased DOX-related toxicity towards
cancer cells compared with control samples heated in an incubator (Fig. 2b and Fig. S5). In
agreement with previous results,[9] free DOX molecules, as well as the TSMs and the TSLs,
displayed slightly greater cytotoxicity at the higher temperature (45 °C) while NSLs showed
no toxic effect on the timescale of the experiments. Importantly, the cytotoxicity of free
DOX and TSLs was significantly enhanced when exposed to controlled GNR-mediated
photothermal heating (45 °C, P <0.05; Fig. 2b). The result suggests that photothermal
heating by GNRs not only enhances cytotoxicty of DOX molecules, but it also induces DOX
release from the heat-sensitive drug carriers, thereby, enhancing the therapeutic effect.
Consistent with the in vitro results, we found that heating of thermosensitive nanoparticles
also improves drug accumulation in tumors in vivo. We first tested the ability of the
thermosensitive nanoparticles to release their contents (NIR fluorescent dyes) in vivo by
heating the tumoral region of the mouse with an external water bath at 45 °C (Fig. 3a and
Fig. S6) Significant fluorescence intensity was observed in the heated tumors relative to the
unheated control tumors. We attribute the increased nanoparticle uptake to heat-induced
dilation of the vascular pores feeding the tumors. [8,10,11] Additionally, bladders from the
mice injected with TSM or TSL containing a surface-attached or encapsulated fluorescent
dye (TSM-VT750 and VT750@TSL, repsetively) displayed strong fluorescence signals
relative to the other formulations, suggesting that these fluorescent payloads are released
into the blood stream selectively upon heating. However, the data indicate that TSMs are
readily dissociated into free lipids in vivo at either temperature studied (Fig. S6).
Having established that application of external heat can trigger drug release in a tumor, we
next tested the ability of injected GNRs to improve nanoparticle drug delivery using the
laser-induced photothermal effect. The biodistribution of NSL and TSL upon photothermal
heating was similar to that of other nanomaterials, with a tendency to undergo significant
clearance into the mononuclear phagocyte system (MPS)-related organs (liver and spleen,
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Fig. 3b).[6,20,26] However, we found that the quantity of DOX accumulated in the GNR-
heated tumors was comparable to that observed in the MPS-related organs, particularly for
the TSM and TSL formulations. Strikingly, the TSLs combined with GNR-mediated heating
resulted in a ~12 ×larger quantity of DOX accumulating in the heated tumor relative to an
unheated tumor. Such a significant excess is difficult to achieve with actively targeted
nanomaterials (i.e., materials containing molecular species that bind specifically to tumors
or tumor-related tissues).[20,26–28] The excess can be attributed to a combination of two
factors: an increase in uptake of nanoparticles through heat-dilated vessel pores and an
increase in diffusion of drug out of the nanocarriers. Once free of the carrier, DOX
molecules are known to bind efficiently to cancer cells in vivo.[29] TSM and NSL
formulations also showed greater accumulation of DOX in GNR-heated tumors, although
the quantities are statistically lower than observed for TSLs (P <0.05). Free DOX molecules
did not accumulate in tumors, even with GNR-mediated heating, presumably due to their
short blood half-life (~5 min) and small molecular size relative to the nanoparticle carriers.
The blood half-life of the liposomal and micellar formulations is much greater (~3 h), and
the data illustrate the significant advantage of using encapsulants for delivery of short-lived
or toxic therapeutics. Microscopic histological analysis of the tumor tissues supports the
macroscopic quantitative DOX biodistribution data. Upon photothermal heating, significant
quantities of DOX were observed in the extravascular region of the tumor for the TSL
formulations, while DOX delivery to the tumor was somewhat limited for NSL and TSM
samples (Fig. 3c).
Finally, we investigated longer-term therapeutic efficacy of the cooperative nanosystem for
treatment of a human xenograft tumor in the mouse model (Fig. 4a–c). We found that the
combination of GNR-mediated heating and the presence of the thermosensitive therapeutic
nanoparticles significantly inhibits tumor growth without displaying significant systemic
toxicity. Controls using the individual components or combinations using non- or weakly
thermosensitive therapeutic nanoparticles, with or without laser irradiation, proved to be less
effective.
In summary, we demonstrate that a pair of synthetic nanoparticles can work together to
detect a diseased site and more effectively deliver chemotherapeutics to the site than
individual nanoparticle treatments. This system relies on GNR transduction of an external
optical signal into a tumor-specific thermal signal that enhances recruitment of circulating
drug carriers into the tumor and triggers drug release from the carriers. GNRs localized in
tumors can be identified in vivo by their intense SERS signals, making it possible to use this
technology in both diagnostic and therapeutic applications. It is important to point out that
non-specific uptake of the drug carriers in the MPS-related organs still remains a problem
with this cooperative nanosystem, although it is significantly reduced relative to
conventional therapies using single targeted drug carriers. The data presented here show that
use of cooperative nanomaterials, in which each of the components has a dedicated function,
can be effective at treating diseased tissues. Furthermore, it illustrates the potential
advantage of dual therapeutic nanomaterials in the precision treatment of more drug-
resistant cancers.
Experimental
GNR Preparation
GNRs containing a CTAB coating and displaying a peak plasmon resonance at 800 nm were
purchased from Nanopartz, inc. and their CTAB coating was replaced with PEG (5kDa)
molecules. To identify particles SERS, 3,3′-Diethylthiatricarbocyanine iodide molecules
were trapped into the PEG coating.
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Therapeutic Nanoparticle Preparation
Nonthermally sensitive DOX liposomes, thermally sensitive DOX liposomes, and DOX-
loaded TSMs were prepared using a modification of published preparations [23,24]. For
fluorophore conjugation (Cy7 or Alexa Fluor 488), the amine-terminated liposomes and
micelles were also prepared. The prepared nanoparticles were intravenously injected in vivo
to ensure that TSM, NSL, and TSL exhibited all similar circulation times (blood half-lives
for all: ~3 h).
Nanoparticle Characterization
TEM images of GNRs, TSMs, NSLs, and TSLs were obtained using a Hitachi H-600A
transmission electron microscope. The hydrodynamic size of GNRs, TSMs, NSLs, and TSLs
was obtained using a Zetasizer ZS90 dynamic-light-scattering machine (Malvern
Instruments, Worcestershire, UK).
SERS Spectral Acquisition
A Horiba Jobin Yvon Labram HR800 spectrometer was used for recording SERS spectra.
Spectra were acquired with a 785-nm diode laser. In vitro SERS spectra of the cyanine-dye-
tagged PEG GNRs were acquired between 100 and 1900 cm−1 of the Raman shift. For in
vivo SERS spectra of cyanine dye-tagged PEG GNRs, 24 h after intravenous injection, in
vivo Raman spectra of the anesthetized mouse were obtained in the Raman shift range 100
to 1900 cm−1, using acquisition times of 30 s (liver and spleen) or 60 s (tumors and skin).
The Raman laser was focused on the anatomical regions corresponding to the tumor, liver,
spleen, and the skin-near tumor.
In vitro Imaging and Cytotoxicity
For fluorescence microscopy, MDA-MB-435 human melanoma cells were incubated with
80 ug DOX/mL of free DOX, TSMs, NSLs, and TSLs per well for 15 min at 37 °C or 45 °C
and rinsed three times with cell medium. The cells were then incubated for an additional 1 hr
at 37 °C in the presence of 10% fetal bovine serum (FBS), fixed with 4% paraformaldehyde,
stained, and observed with a fluorescence microscope (Nikon, Tokyo, Japan). Cytotoxicity
of the in vitro cooperative nanoystem was performed using MDA-MB-435 human
melanoma cells. Cells were incubated with free DOX, TSMs, NSLs, or TSLs at different
concentrations and GNRs at 7 μg Au mL−1 for 15 min at 37 °C or 45 °C in a cell incubator.
For laser-induced (photothermal) heating, samples were irradiated for 15 min with ~0.75 W
cm−2 of 810-nm laser light, either in the presence or absence (control) of GNRs, while
maintaining an average solution temperature of ~45 °C (monitored by IR thermographic
surveillance). After irradiation, the cells were rinsed three times with cell medium. The cells
were then incubated for an additional 48 h at 37 °C. The cytotoxicity of free DOX, TSMs,
NSLs, and TSLs was evaluated using an MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] assay (Invitrogen).
In vivo Behavior of Thermosensitive Nanoparticles (Laser Photothermal Heating)
First, GNRs were intravenously injected into mice bearing bilateral MDA-MB-435 human
melanoma tumors (10 mg Au kg−1). At 72 h post-injection, when the GNRs were
completely cleared from the blood stream, therapeutic molecules or nanoparticles (5 mg
DOX kg−1) were systemically administered and either the right or the left flank (area where
the tumor is located) was immediately irradiated with near-infrared (NIR)-light (~0.75 W
cm−2 and 810 nm) for 30 min, maintaining the average tumor surface temperature at ~45 °C
(monitored by IR thermographic observation). At 24 h post-injection of the therapeutic
nanoparticles, the tissues were harvested, weighed, and homogenized to release DOX from
the tissues. Following homogenization, the samples were centrifuged and supernatants of
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samples were analyzed for DOX fluorescence using a fluorescence microplate reader
(Molecular Devices, SpectraMax GeminiEM).
In vivo Therapeutic Studies
At 72 h post-injection of GNR (10 mg Au kg−1), saline, therapeutic molecules or
nanoparticles (3 mg DOX kg−1) were systemically administered and one flank of the mouse
(the area where the tumor is located) was either not irradiated or immediately irradiated with
NIR-light (~0.75 W cm−2 and 810 nm) for 30 min, maintaining an average tumor surface
temperature of ~45 °C (monitored by IR thermographic observation). Each therapeutic
cohort included ~5–7 mice. After the single treatment, tumors were measured and mice were
weighed at 3 day intervals over a period of 3 weeks. All animal work was performed in
accordance with the institutional animal protocol guidelines in place at the Massachusetts
Institute of Technology, and it was reviewed and approved by the Institute’s Animal
Research Committee. Student’s t-test was used for statistical analysis of the results.
A full description of the methods is available as Supporting Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Characterization of the two components of a cooperative nanosystem. a) Schematic diagram
depicting the cooperative nanomaterials system. b) TEM images of PEG-coated GNR, TSM,
NSL, and TSL. The scale bars are all 100 nm. c) Optical image, thermal images, and Raman
spectra of a mouse depicting the multifunctionality of the GNRs. The GNRs act as thermal
transducers or as SERS contrast agents when irradiated with a laser of the appropriate
wavelength and intensity. The mouse, bearing a MDA-MB-435 tumor, was injected
intravenously with GNRs (10 mg Au kg−1). The IR thermographic maps shown were
obtained 24 h post-injection; the left image was acquired immediately before and the right
image 5 min after onset of irradiation with a diode laser (λ = 810 nm, 0.75 W cm−2). Raman
spectra (5 acquisitions of 60 s each) were acquired from the tumoral region (red trace) and
from skin near the tumor (blue trace). The GNRs in this experiment were labeled with a
cyanine dye and the peaks in the trace correspond to the SERS spectrum cyanine dye
(verified by in vitro control). d) Amount of DOX released in vitro from the liposome and
micelle formulations used in this study, as a function of temperature. The samples were
incubated for 10 min at the indicated temperatures and the amount of free DOX was
quantified by fluorescence spectroscopy, relative to a standard curve. Values represent the
mean and the error bars indicate standard deviation.
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Figure 2.
Temperature-induced intracellular drug delivery and cytotoxicity of the cooperative
nanosystem. a) Images showing the intracellular delivery of DOX (red) from various
therapeutic nanoparticle formulations to MDA-MB-435 human melanoma cells, at two
different temperatures. The cells were incubated with free DOX, TSM, NSL, and TSL for 15
min at the indicated temperatures in a cell incubator. All formulations contain 80 μg mL−1
of DOX. Samples were rinsed three times with cell medium, then incubated for an additional
1 h at 37 °C and imaged. The nuclei were stained with 4′-6-diamidino-2-phenylindole
(DAPI, blue). The scale bar indicates 100 μm. b) Cytotoxicity of various photothermally
activated therapeutic nanoparticle formulations to MDA-MB-435 human melanoma cells,
quantified by MTT assay (*P <0.05). The cells were incubated with free DOX, TSMs,
NSLs, and TSLs at the indicated concentrations. GNR+ and GNR− indicate the presence or
absence of GNRs (7 μg Au mL−1) in the mixture, respectively. L+ and L− indicate the
presence or absence of NIR irradiation (810 nm, 0.75 W cm−2 for 15 min), respectively.
After irradiation (or 15 min in the dark for L− samples), the cells were rinsed three times
with the cell-culture medium and incubated for an additional 48 h at 37 °C before
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administration of the MTT assay. Values represent the mean and the error bars indicate
standard deviation.
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Figure 3.
Fate of thermally responsive nanostructures in vivo. a) Fluorescence images of organs from
mice, where one tumor was heated at 45 °C for 30 min immediately after injection of
various VT750-labeled nanoparticle formulations. The NIR-fluorescent molecular probes
VT750 (750 nm excitation, 780 nm emission) were either attached to the nanoparticle
surface (TSM-VT750, NSL-VT750, and TSL-VT750) or encapsulated in the internal space
of nanoparticles (VT750@NSL and VT750@TSL). Mice bearing bilateral MDA-MB-435
tumors were intravenously injected with various VT750-labeled nanoparticle formulations
and one tumor was immediately heated at 45 °C for 30 min in a temperature-controlled
water bath. At 2 h post-injection, the tissues were collected from the mice and imaged with a
NIR fluorescence imaging system. b) Biodistribution of DOX for various therapeutic
nanoparticle formulations after GNR-mediated photothermal heating. Mice bearing bilateral
MDA-MB-435 tumors were injected with GNRs (10 mg Au kg−1). At 72 h post-injection,
the indicated free DOX or therapeutic nanoparticle formulation was administered and one
tumor was immediately irradiated (810 nm, ~0.75 W cm−2) for 30 min while maintaining an
average tumor surface temperature of ~45 °C under IR thermographic surveillance. 24 h
post-injection of the therapeutic nanoparticles, the tissues were collected from the mice and
the native fluorescence intensity from DOX was quantified as a percentage of injected dose
per tissue mass. Values represent the mean and the error bars indicate standard deviation.
The differences in DOX concentration released from TSL in the heated tumor, relative to the
other formulations (TSM and NSL), are significant (*P <0.05). c) Histological analysis of
DOX distribution in MDA-MB-435 tumors treated with free DOX or the indicated
therapeutic nanoparticle formulations and then subjected to GNR-mediated photothermal
heating. The tissues were collected for hisotological analysis 6 h post-injection of the
therapeutic nanoparticles (red: DOX, blue: DAPI nuclear stain, green: Alexa Fluor 488
labeled on the therapeutic nanoparticles). Abbreviations: NP, nanoparticle; T+, tumor heated
to 45 °C; T−, tumor maintained at ambient temperature; Li, liver; Sp, spleen; K, kidney; Lu,
lung; Bl, blood; Br, brain; H, heart. The scale bar indicates 200 μm.
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Figure 4.
Tumor therapy using cooperative nanosystem. a) Relative tumor volume in different
treatment groups (n = ~5–7 mice per trace) for MDA-MB-435 human melanoma tumors.
Mice bearing bilateral MDA-MB-435 tumors were injected with GNRs (10 mg Au kg−1).
After 72 h, a single dose of the indicated saline, free DOX, or various therapeutic
nanoparticle formulations (3 mg DOX kg−1) was administered through tail vein injection
and one tumor was irradiated with a NIR laser (810 nm, ~0.75 W cm−2) for 30 min, while
maintaining an average tumor surface temperature of ~45 °C (monitored by IR
thermographic surveillance). Tumor volumes were quantified every 3 d post-irradiation. The
differences between TSL plus irradiation and all other groups were significant (*P <0.05 for
12 and 15 days and **P <0.02 for 18 and 21 days) in the tumor volume change curves. b)
Representative images of treated tumors in the live animals for the indicated treatments (21
days post-treatment). Scale bar indicates 1 cm. c) Mouse mass as a function of days post-
treatment for the indicated treatment groups. L+ and L− indicate animals whose tumors
received NIR irradiation, or no irradiation, respectively, 72 h after GNR injection. Normal
growth of all groups is observed for 3 weeks post-treatment. TSL, TSM, and NSL are the
different nanoparticle formulations, defined in Figure 2.
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